medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2002, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2002; 15 (4)

Ultra-short antituberculous treatment (2HRZ/2H3R3) vs standard treatment (2HRZ,4H3R3) in fixed

Olvera CR, Ramos EJ, García CAE, Hernández ZNM

Language: Spanish
References: 23
Page: 214-219
PDF size: 127.93 Kb.


ABSTRACT

Introduction: Antituberculous chemotherapy is the best control measure for tuberculosis because incidence and mortality rates as well as infection sources are reduced. Evaluations of treatment in cohorts of pulmonary Tb patient smears (+), showed that 70% exhibited negative smear after four weeks of supervised treatment with fixed drug (FD) combination of HRZ, and nearly 90% after 8 weeks. Objectives: To compare efficacy of two treatment regimes: four and six months duration, as well as abandon, failure, and death rates, and relapses at 6, 12 and 18 months after treatment. Methods: 34 pulmonary Tb patient smears (+) were randomly enrolled in the assay; 20 in ultra-short regime and 14 in standard regime, under TAES (DOTS) strategy. Results: At four months of treatment, 100% Tb patients of two groups, had negative baciloscopy; and 0% of failures, defaults or deaths. There was one relapse six months after the end of the ultra-short regime, and no more relapses at 18 months of follow-up. Conclusion: Both regimes were 100% effective, TAES (DOTS) strategy reduced or avoided defaulters and failures. The ultra-short regime is not recommendable in the treatment of pulmonary Tb patient smear (+), because of the 5% rate of relapse. Treatment success depends on compliance.


REFERENCES

  1. Global tuberculosis situation and tuberculosis control programme. WHO/TB/91.159.

  2. Zacarías F, González RS, Cuchi P, Vánez A, Peruga A, Mazin R, y colaboradores. El sida y su interacción con la tuberculosis en América Latina y el Caribe. Bol Sanit-Panam 1994;116:250-262.

  3. Secretaría de Salud. Tratamiento de la tuberculosis. México, 1984.

  4. Secretaría de Salud. Tratamiento de la tuberculosis. Guía para el médico general. México, 1989.

  5. Farga CV. Tuberculosis. Tratamiento de la tuberculosis, principios generales. Santiago de Chile: Universitaria, 1989.

  6. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62 dose, 6-months therapy for pulmonary and extrapulmonary tuberculosis a twice –weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-415.

  7. Singapore tuberculosis service/british medical research council long term follow-up. A clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:779-783.

  8. Singapore tuberculosis service/british medical research council. Clinical total of six month and four month regimens chemotherapy in the treatment of pulmonary tuberculosis the results to 30 monts. Tubercle 1981;62:95-102.

  9. Tuberculosis Research Center, Madras, and National Tuberculosis Institute Bangalore. A controlled clinical trial of 3. And 5 moth regimens in the treatment of pulmonary tuberculosis in south India. Am Rev Respir Dis 1986;134:227.33.

  10. Yáñez VLB, Guadalupe Q, Rodriguez J. Use of dots in pilot areas of Mexico. Int J Tuberc Lung Dis 1997;1:1S-68S.

  11. Ngamvithayapong J, Ishikawa N, Yoshiyama T. Directly observed therapy for tuberculosis (dot): International evidences and perspectives. Int J Tuberc Lung Dis 1997;1:1S-68S.

  12. Malla P, Bam DS, Sharma NR. Preliminary report of four national demonstration dots treatment centres of Nepal. Int J Tuberc Lung Dis 1997;1:1S-69S.

  13. Mokhtar A, El Din, Hazem M, Van Maaren P. Ambulatory dots: Utilizing phc centres in Egypt. Int J Tuberc Lung Dis 1997;1:1S-70S.

  14. Khalilzadeh S, Baghaii N, Masjedi MR. Study of 355 smear positive tuberculosis patients according to dots. Int J Tuberc Lung Dis 1997; 1:1S-70S.

  15. Khomenko A, Punga V, Grishina T, Golyshevskaya V, Rybka L, Korneev A, et al. Results of a pilot project of TB control in the ivanovo oblast, Russia. Int J Tuberc Lung Dis 1997;1:1S-71S.

  16. Safarian M, Zalesky R, Minasian G. The pleliminary results of the antituberculosis standardized short-course chemotherapy in the WHO pilot project’s areas of Armenia. Int J Tuberc Lung Dis 1997;1:1S-72S.

  17. Suarez PG, Alarcón E, Sabogal C, Poriocutero J, Zavala D, Canales R. Tuberculosis cotrol in Perú. Cure rates. Int J Tuberc Lung Dis 1997; 1:1S-73S.

  18. Golubchikova VT, Lyagoshima TV, Strellis AK, Sharaburova OE, Yanova GV, Tonkel TP, et al. A comparison of short course chemotherapy (SCC) with traditional Russian therapy methods in the treatment of WHO category III TB patients. Int J Tuberc Lung Dis 1997; 1:1S-79S.

  19. Kuruc V, Pavlovic S, Radakovic D. Efficiency of antituberculosis treatment due to drug combination. Int J Tuberc Lung Dis 1997;1:1S- 80S.

  20. Vasilescu C, Vasiliu V, Panescu M. The exclusive ambulatory treatment of TB. Int J Tuberc Lung Dis 1997;1:1S-80S.

  21. Golubovic S, Dordevic J. Velocity of sputum conversion in active pulmonary tuberculosis (PT) in relation to radiographic extent. Int J Tuberc Lung Dis 1997;1:1S-106S.

  22. Salek S, Masjedi M, Velayati A, Taghizadeh R, Ghazi KS, Mansoori D. Dots experience in Iran, varamin pilot study. Int J Tuberc Lung Dis 1997;1:1S-140S.

  23. Ramos EJ, Villalba CJ, Rodríguez FS, Olvera CR. Ultra short–term antituberculosis treatment with the fixed drug combination scheme. Tuberc Lung Dis 1995;76:103.




2020     |     www.medigraphic.com